No Data
No Data
Hong Kong stock market anomaly | Asymchem Laboratories (06821) fell more than 4%, leading the CRO concept. The industry's performance is generally under pressure due to the decline in investment and financing in the pharmaceutical industry.
CRO concept stocks fell today. As of press time, Asymchem Laboratories (06821) fell 3.74%, at HKD 39.9; Tigermed (03347) fell 3.67%, at HKD 30.2; Pharmaron (03759) fell 3.06%, at HKD 8.55; Wuxi AppTec (02359) fell 2.88%, at HKD 32.05.
Sinolink: The results of the negotiations on drug prices in the United States have been announced, and the continuous procurement of medical devices domestically is ongoing.
Bullish on the development of the domestic medical devices industry in the second half of the year, with the industry's purchasing demand expected to accelerate recovery. At the same time, domestic leading companies in sub-sectors such as ultrasound and endoscopy, due to their strong competitiveness, are expected to further increase market share, with sales growth and profitability expected to return to an upward trend.
Pharmaron (03759) plans to acquire 80 million yuan of unsubscribed but yet-to-be paid AstraZeneca fund shares held by Jiangsu Yuyue Medical Equipment & Supply.
Pharmaron (03759) has announced to fully leverage its industry-leading position in medical and health fields as well as its globalized industry chain.
Jiangsu Yuyue Medical Equipment & Supply (002223.SZ) intends to transfer its shares of industrial investment fund to Pharmaron.
On August 16th, Gelunhui reported that Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (002223.SZ) announced that the company signed a "Transfer Agreement of Property Interests in Wuxi AstraZeneca CITIC Entrepreneurial Investment Partnership Enterprise (Limited Partnership)" with Pharmaron (Beijing) New Drug Technology Co., Ltd. (referred to as "Pharmaron"), CITIC Private Equity Funds Management Co., Ltd. (referred to as "CITIC Private Equity"), and AstraZeneca Business Consulting (Wuxi) Co., Ltd. (referred to as "AstraZeneca") on August 16, 2024. The company transferred its subscribed capital contribution to the partnership enterprise of RMB 80 million to Pharmaron at a price of RMB 0.
Pharmaron (03759.HK) held a board of directors meeting on August 27 to review and approve its mid-term performance.
Pharmaron (03759.HK) announced on August 14th that the board of directors meeting will be held on Tuesday, August 27th, 2024 to review and approve the interim performance of the company and its subsidiaries for the six months ended June 30th, 2024, which includes its release.
PHARMARON: NOTICE OF BOARD MEETING
No Data